Awaiting development: Guidance and quality standards
Showing 1 to 5 of 5
| Title | Type |
|---|---|
| Avexitide for treating hypoglycaemia after bariatric surgery [TSID12233] | Technology appraisal guidance |
| Datopotamab deruxtecan with durvalumab for treating triple-negative breast cancer when there is residual invasive disease after neoadjuvant systemic treatment and surgery [ID6643] | Technology appraisal guidance |
| Dexamethasone intracanalicular insert for treating inflammation and pain after cataract surgery [ID1154] | Technology appraisal guidance |
| Durvalumab in combination for untreated advanced ovarian, fallopian tube or primary peritoneal cancer before and after surgery [ID6254] | Technology appraisal guidance |
| Pembrolizumab with chemotherapy for adjuvant treatment of newly diagnosed high-risk endometrial cancer after surgery with curative intent [TSID11808] | Technology appraisal guidance |